Psoriasis Club forum

Emerging evidence suggests a link between psoriasis (PSO), psoriatic arthritis (PSA), and periodontitis (PE) Quote: Objectives: Emerging evidence suggests a link between psoriasis (PSO), psoriatic arthritis (PSA), and periodontitis (PE), similar to other systemic conditions. This study aimed to evaluate the levels of Porphyromonas gingivalis , Treponema denticola , Tannerella forsythia , Prevotella intermedia , and Aggregatibacter actinomycetemcomitans (qPCR), as well as salivary biomarkers RANKL, OPG, Survivin, and IL-17 (ELISA) in individuals with PSO and PSA, compared to non-psoriatic controls with and without PE. Subjects and Methods: From a case–control study ( n = 655), 192 non-smokers and non-diabetics were randomly selected and divided into six gender-matched groups ( n = 32 each): control, PSO, and PSA, with and without PE. Results: Higher counts of P. gingivalis , T. forsythia , and T. denticola were found in individuals with PE, particularly in PSA + PE and PSO + PE groups, along with significant intergroup differences in IL-17 and survivin, with higher levels in PSA than PSO and controls. In PSA + PE individuals, OPG, IL-17, and survivin were significantly increased. Positive correlations were observed between RANKL, IL-17, survivin, and clinical periodontal parameters, with negative correlations for OPG ( p < 0.001). Conclusions: Psoriatic individuals with PE show higher levels of classical red-complex periodontopathogens and heightened inflammatory biomarker lev

This study looked at Generalised Pustular Psoriasis (GPP) and mortality risk in English patients. Quote: Generalised Pustular Psoriasis Epidemiology Assessed Generalised pustular psoriasis (GPP) prevalence increased by more than 50% in England between 2008 and 2022, while patients with GPP had substantially higher mortality risk and reduced life expectancy compared with people without the condition. The population-based cohort study used primary care and hospital records linked with mortality, ethnicity and deprivation data. Among 25.8 million people, 991 patients with GPP were identified, of whom 63% were female, 86% were White, 10% were Asian and 3% were Black, Mixed or Other. GPP prevalence increased from 20.9 per million in 2008 to 32.5 per million in 2022. Incidence remained stable until 2016 before increasing, reaching 4.9 per million person-years. The mean age at GPP onset was 51.4 years, with onset occurring earlier among Asian patients than White patients. Mortality Risk Increased With GPP Patients with GPP had more than three times the risk of all-cause mortality compared with people without GPP (adjusted hazard ratio [aHR]: 3.19; 95% confidence interval [CI]: 2.58–3.91). Mortality rates were also elevated for several specific causes of death, including neoplasms, respiratory, digestive and circulatory diseases. The strongest association was observed for sepsis, for which the mortality risk was substantially higher among patients with GPP (aHR: 9.76; 95% CI: 4.92–19

Hi everyone I’m new to this forum, I am 70 years old old and it looks like I am suffering from some form of psoriasis, not been officially diagnosed yet, have to wain until early November to see a dermatologist, have Red blotches on my forehead face neck backs of, also itching to my scalp, backs of hands forearms neck shoulders and back small round red scales very itchy, this all came on over the last 3 months, not sure of the trigger maybe because I am on beta blockers or too much time in the sun, so that’s me, would welcome any suggestions to stop the itching (driving me insane). Started using ice packs ? Thanks for looking.

Hi everyone I’m new to this forum, I am 70 years old old and it looks like I am suffering from some form of psoriasis, not been officially diagnosed yet, have to wain until early November to see a dermatologist, have Red blotches on my forehead face neck backs of, also itching to my scalp, backs of hands forearms neck shoulders and back small round red scales very itchy, this all came on over the last 3 months, not sure of the trigger maybe because I am on beta blockers or too much time in the sun, so that’s me, would welcome any suggestions to stop the itching (driving me insane). Started using ice packs ? Thanks for looking.

Findings uncover a novel pathogenic mechanism in psoriasis, wherein Calcium-binding protein 39 (CAB39) K196 decrotonylation drives keratinocyte dysfunction. Quote: Psoriasis is a chronic and recurrent inflammatory dermatosis characterized by dysregulated keratinocyte proliferation. Calcium-binding protein 39 (CAB39), a critical regulatory scaffold for Sterile 20 kinase, has been implicated in multiple diseases, but its role and regulatory mechanisms in psoriasis remain unclear. Here, we found that CAB39 was significantly upregulated in psoriatic lesions, and CAB39 knockdown inhibited keratinocyte proliferation and attenuated psoriasis progression. Further investigations revealed that CAB39 crotonylation at lysine 196 was reduced in psoriatic lesions. Functional analyses in normal human epidermal keratinocytes (NHEKs) showed that the crotonylation-deficient CAB39 K196A mutant significantly promoted keratinocyte hyperproliferation and glycolytic remodeling. Dysregulation of modifying enzymes, including downregulated CBP and upregulated HDAC2/3, drives CAB39 K196 decrotonylation in psoriasis. Mechanistically, CAB39 K196 decrotonylation weakens its binding affinity to STRAD (STE20-related adaptor), disrupts the stability of the CAB39-STRAD-LKB1 (liver kinase B1) complex, and inhibits the LKB1/AMPK signaling pathway. Concurrently, decrotonylated CAB39 promotes phosphatidic acid (PA, a lipid second messenger) synthesis, activating the pro-proliferative PA/MAPK/mTOR signaling cascad

Findings uncover a novel pathogenic mechanism in psoriasis, wherein Calcium-binding protein 39 (CAB39) K196 decrotonylation drives keratinocyte dysfunction. Quote: Psoriasis is a chronic and recurrent inflammatory dermatosis characterized by dysregulated keratinocyte proliferation. Calcium-binding protein 39 (CAB39), a critical regulatory scaffold for Sterile 20 kinase, has been implicated in multiple diseases, but its role and regulatory mechanisms in psoriasis remain unclear. Here, we found that CAB39 was significantly upregulated in psoriatic lesions, and CAB39 knockdown inhibited keratinocyte proliferation and attenuated psoriasis progression. Further investigations revealed that CAB39 crotonylation at lysine 196 was reduced in psoriatic lesions. Functional analyses in normal human epidermal keratinocytes (NHEKs) showed that the crotonylation-deficient CAB39 K196A mutant significantly promoted keratinocyte hyperproliferation and glycolytic remodeling. Dysregulation of modifying enzymes, including downregulated CBP and upregulated HDAC2/3, drives CAB39 K196 decrotonylation in psoriasis. Mechanistically, CAB39 K196 decrotonylation weakens its binding affinity to STRAD (STE20-related adaptor), disrupts the stability of the CAB39-STRAD-LKB1 (liver kinase B1) complex, and inhibits the LKB1/AMPK signaling pathway. Concurrently, decrotonylated CAB39 promotes phosphatidic acid (PA, a lipid second messenger) synthesis, activating the pro-proliferative PA/MAPK/mTOR signaling cascad

This months poll above asks: Do you talk to others about psoriasis ? Voting is open to members and guests, our members can also leave a comment if they wish. I would talk to anyone about it if they wanted to listen.

This months poll above asks: Do you talk to others about psoriasis ? Voting is open to members and guests, our members can also leave a comment if they wish. I would talk to anyone about it if they wanted to listen.

This study aimed to determine whether the short-term response to biologics in biologic-naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Quote: Objective: We aimed to determine whether the short-term response to biologics in biologic-naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods: Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis. Patients were considered in the early treatment group if they had started on biologic therapy within two years of PsA diagnosis; otherwise, they were considered in the delayed treatment group. The primary outcome was ≥50% reduction in the Disease Activity Index for Psoriatic Arthritis (DAPSA) score at six months. The secondary outcome was Psoriasis Area and Severity Index (PASI) 75, defined as ≥75% improvement in the PASI score at six months. Logistic regression was used to examine the association between early treatment and disease outcomes at six months. Propensity scores were used to account for differences between the groups at the baseline visit. Results: Of the 228 included patients, 71 patients were in the early treatment group, and 157 patients were in the delayed treatment group. There were significant differences in the time from PsA diagnosis to biologic treatments over the decades. The propensity score regression adjusted analysis did not suggest a d

Results from clinical field tests to evaluate cardiorespiratory fitness in psoriatic arthritis patients. Quote: Objective: Cardiorespiratory fitness (CRF) is reduced in patients with psoriatic arthritis (PsA), highlighting the need for a consistent assessment of CRF in clinical practice. This study aimed to examine the associations between outcomes of clinical field tests, namely six-minute walk test (6MWT) and handgrip strength (HGS), and CRF, as well as to evaluate the accuracy of these clinical field tests in detecting impaired CRF in patients with PsA. Methods: Distance walked during 6WMT (six-minute walk distance [6MWD]), HGS by hand dynamometry, and maximal CRF as peak oxygen uptake (VO2peak, milliliters per minute per kilogram) by cardiopulmonary exercise testing were assessed. 6MWD and HGS were compared to reference charts of the general population using one-sided t -tests. Spearman rank correlation coefficients (rs), multivariable linear regression models, and receiver operating curves were analyzed to study associations. Results : In 80 patients with PsA, 6MWD was strongly associated with VO2peak (rS = 0.65, P 0.05). A higher 6MWD was moderately to strongly correlated with more favorable outcomes regarding disease activity, cardiometabolic risk, and patient-reported outcomes. No or only weak associations between HGS and VO2peak as well as clinical outcomes were noted. Conclusion: 6MWD was strongly associated with VO2peak, was moderately to strongly correlated with i

This study aimed to determine whether the short-term response to biologics in biologic-naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Quote: Objective: We aimed to determine whether the short-term response to biologics in biologic-naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods: Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis. Patients were considered in the early treatment group if they had started on biologic therapy within two years of PsA diagnosis; otherwise, they were considered in the delayed treatment group. The primary outcome was ≥50% reduction in the Disease Activity Index for Psoriatic Arthritis (DAPSA) score at six months. The secondary outcome was Psoriasis Area and Severity Index (PASI) 75, defined as ≥75% improvement in the PASI score at six months. Logistic regression was used to examine the association between early treatment and disease outcomes at six months. Propensity scores were used to account for differences between the groups at the baseline visit. Results: Of the 228 included patients, 71 patients were in the early treatment group, and 157 patients were in the delayed treatment group. There were significant differences in the time from PsA diagnosis to biologic treatments over the decades. The propensity score regression adjusted analysis did not suggest a d

Results from clinical field tests to evaluate cardiorespiratory fitness in psoriatic arthritis patients. Quote: Objective: Cardiorespiratory fitness (CRF) is reduced in patients with psoriatic arthritis (PsA), highlighting the need for a consistent assessment of CRF in clinical practice. This study aimed to examine the associations between outcomes of clinical field tests, namely six-minute walk test (6MWT) and handgrip strength (HGS), and CRF, as well as to evaluate the accuracy of these clinical field tests in detecting impaired CRF in patients with PsA. Methods: Distance walked during 6WMT (six-minute walk distance [6MWD]), HGS by hand dynamometry, and maximal CRF as peak oxygen uptake (VO2peak, milliliters per minute per kilogram) by cardiopulmonary exercise testing were assessed. 6MWD and HGS were compared to reference charts of the general population using one-sided t -tests. Spearman rank correlation coefficients (rs), multivariable linear regression models, and receiver operating curves were analyzed to study associations. Results : In 80 patients with PsA, 6MWD was strongly associated with VO2peak (rS = 0.65, P &t 0.001), with the multivariable linear regression model, consisting of 6MWD and 6MWT heart rate response and adjusted for relevant covariates, explaining 70% of variance in VO2peak. The threshold of 108% predicted 6MWD had sensitivity of 75% and specificity of 64% to identify patients with impaired CRF. 6MWD and HGS were not significantly decreased compared